Q&A: Determined to not repeat mistakes from the last pandemic, Andrey Zarur talks about latest deal with Serum Institute
The Massachusetts biotech GreenLight made waves Monday with the announcement of its licensing deal with the Serum Institute of India. Three of its mRNA products, starting with its shingles vaccine, will be produced by Serum in a deal that piggybacks off of its $10 million investment from November.
GreenLight is riding high off of its reverse merger that netted itself a $1.5 billion valuation, after it merged with the SPAC Environmental Impact Acquisition Corp. It’s still working on experimental vaccines and therapies using mRNA technology for the seasonal flu and sickle cell disease, a long way from where it originally got its start: shaking up the pesticides market for agriculture.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.